United States Disseminated Intravascular Coagulation Diagnosis Market 2026 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Disseminated Intravascular Coagulation Diagnosis Market is projected to reach at a CAGR of 3% during the forecast period (2023-2030).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/disseminated-intravascular-coagulation-diagnosis-market?sb

Key Development:

United States: Recent Developments in DIC Diagnosis

✅ In Nov 2025-Jan 2026, U.S. hematology forums and clinics increasingly adopted updated ISTH criteria in case discussions and clinical audits, reflecting a shift toward dynamic, etiology‐based diagnostic consideration rather than relying solely on traditional static scoring systems.

✅ In August 2025, the International Society on Thrombosis and Haemostasis (ISTH) released updated DIC definitions and diagnostic criteria emphasizing phase‐based classification (pre‐DIC, early‐phase, overt DIC), improving clarity on laboratory thresholds such as D‐dimer, platelet count, and PT‐INR for earlier diagnosis of coagulopathy across clinical contexts.

✅ In August 2025, the updated ISTH framework introduced tailored diagnostic approaches for underlying conditions like sepsis‐induced coagulopathy, promoting the sepsis‐induced coagulopathy score for early‐phase DIC detection before overt symptoms, strengthening diagnostic sensitivity in critical care.

✅ In late 2025, the ISTH Scientific and Standardization Committee proposed refinements to overt DIC diagnostic scoring, encouraging more precise and earlier identification by modifying consensus‐driven definitions and phenotypic classifications (thrombotic vs hemorrhagic), expected to influence U.S. clinical practice.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=disseminated-intravascular-coagulation-diagnosis-market

Japan: Recent Developments in DIC Diagnosis

✅ In Jan 2026, Japanese clinical practice uptake of the 2024 DIC guidelines highlighted tailored diagnostic approaches for different DIC contexts (e.g., sepsis, solid cancers), prioritizing early identification and stratification of acute vs chronic/coagulopathy patterns in hospital protocols.

✅ In early 2025, the Japanese Society on Thrombosis and Hemostasis published the DIC Practice Guidelines 2024 outlining flexible diagnostic strategies, recommending use of multiple diagnostic criteria (JMHW, ISTH overt DIC, JAAM, and emerging JSTH criteria) based on patient context for improved accuracy.

✅ In the recent Japanese DIC guidelines, obstetrical DIC diagnosis and management received focused guidance, emphasizing specific diagnostic parameters like fibrinogen levels and laboratory markers to differentiate obstetrical DIC cases and streamline clinical workflows.

✅ In early 2026, guideline‐based discussions in Japan stressed the importance of adapting diagnostic scoring and clinical judgment, given the diversity of DIC presentations, reinforcing use of comprehensive algorithms rather than single‐test reliance for accurate DIC diagnosis.

Key Players:

=> Abbott, AdvaCare Pharma, Axis-Shield Diagnostics Ltd, Eurolyser Diagnostica GmbH, Quidel Corporation, CTK Biotech, Inc., AccuBioTech Co., Ltd., Getein Biotech, Inc., Siemens Healthcare GmbH, PHC Corporation

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/disseminated-intravascular-coagulation-diagnosis-market?sb

Key Segments:

By Diagnosis

D-dimer holds 20% share, driven by its critical role in diagnosing blood clotting disorders, venous thromboembolism, and COVID-19 related coagulopathies. Complete Blood Count (CBC) with Blood Smear Exam dominates with 25%, reflecting broad adoption in routine hematology, patient monitoring, and general diagnostics. Partial Thromboplastin Time (PTT) accounts for 15%, widely used for monitoring anticoagulant therapy and clotting factor deficiencies. Prothrombin Time (PT) represents 20%, supported by its use in liver disease evaluation, anticoagulant monitoring, and coagulation studies. Fibrinogen Blood Test holds 10%, driven by demand in bleeding and clotting disorders assessment. Others make up 10%, including specialized coagulation and hematology tests.

By End-Users

Hospitals lead with 50% share, driven by inpatient and outpatient testing requirements and high patient throughput. Diagnostic Centers account for 35%, fueled by outpatient testing, preventive health checkups, and specialized coagulation and hematology testing. Other End-Users represent 15%, including research laboratories, academic institutions, and point-of-care facilities.

By Region

North America - 35% Share
North America leads with 35%, supported by advanced healthcare infrastructure, high prevalence of coagulation disorders, and strong adoption of diagnostic testing in hospitals and labs in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, driven by preventive healthcare initiatives, well-established diagnostic centers, and high healthcare spending in Germany, U.K., France, Italy, and neighboring countries.

Asia Pacific - 30% Share
Asia Pacific accounts for 30%, fueled by rising healthcare awareness, increasing hospital and diagnostic center capacities, and growing prevalence of cardiovascular and coagulation disorders in China, India, Japan, South Korea, and Southeast Asia.

Latin America - 5% Share
Latin America represents 5%, supported by urban hospital networks, diagnostic center growth, and government health programs in Brazil, Mexico, and Argentina.

Middle East & Africa - 5% Share
The Middle East & Africa hold 5%, driven by rising healthcare infrastructure investments and growing diagnostic testing demand in GCC countries, South Africa, and surrounding regions.

FAQ

Q: What is the growth rate of the Disseminated Intravascular Coagulation Diagnosis Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 3% during the forecast period from 2023 to 2030.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.